Veradermics, Incorporated (NYSE:MANE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Veradermics, Incorporated (NYSE:MANE) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $153.00.

Several analysts have weighed in on MANE shares. Needham & Company LLC lifted their target price on Veradermics from $136.00 to $164.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Leerink Partners increased their price target on Veradermics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Citigroup raised their price target on Veradermics from $135.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Jefferies Financial Group lifted their price objective on shares of Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, UBS Group set a $170.00 price objective on shares of Veradermics in a report on Wednesday, July 15th.

Veradermics Stock Up 0.4%

Shares of NYSE:MANE opened at $105.05 on Friday. The company has a 50 day moving average price of $108.02. Veradermics has a 52 week low of $32.00 and a 52 week high of $131.24. The firm has a market capitalization of $4.39 billion and a price-to-earnings ratio of -79.58.

Veradermics (NYSE:MANE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

Veradermics Company Profile

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.